Navigation Links
Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Date:5/16/2012

f people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit http://www.amgen.com/. Follow us on http://twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of May 16, 2012 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identif
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
2. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
3. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... NEWARK, Calif. , May 26, 2015 Depomed, ... be presenting at two healthcare conferences in June. ... The presentation at the Jefferies conference is scheduled for 3:00 ... The 2015 JMP Securities Life Sciences Conference in ... scheduled for 11:30 am EDT (8:30 am PDT) Wednesday, June ...
(Date:5/26/2015)... ST. LOUIS , May 26, 2015   ... specialty biopharmaceutical company, today announced that it has extended ... Awards program to July 31, 2015. The program awards ... therapeutic areas. The Mallinckrodt Research Fellowship Awards ... fellows and their education. The program will award a ...
(Date:5/26/2015)... May 26, 2015   Generational Equity , a ... is pleased to announce the acquisition of its client, ... Spokane, Washington , by Mi-Med Supply ... April 30, 2015. Peaks & Plains ... region, selling medical, incontinent, nutritional, patient care, and housekeeping ...
Breaking Medicine Technology:Depomed To Present At Healthcare Conferences In June 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 2Mallinckrodt Extends Deadline For 2015 Research Fellowship Program 3Generational Equity Announces the Acquisition of Peaks & Plains Inc. by Mi-Med Supply 2
... and AMSTERDAM, August 10, 2011 Agendia, ... the 12th St. Gallen International Breast Cancer Conference (2011) ... - classifying patients by the particular biological subtype of ... cancer patients. According to the panel, "it is no ...
... is unpredictable and can be even more so when you ... sneezing or itchy, watery eyes just might earn you top ... Facebook.  Allergy sufferers are invited to upload a short video ... win $5,000 toward a fun-filled adventure where they can enjoy ...
Cached Medicine Technology:International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 2Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 3Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 4
(Date:5/26/2015)... India (PRWEB) May 26, 2015 Surging ... 2015, one of the leading online health and wellness ... impact to the online community. It has proven ... people to read articles, watch videos, ask questions and ... The launch of the official Consumer Health Digest YouTube ...
(Date:5/26/2015)... 2015 Irwin Gross, M.D., Accumen, ... hospital-wide Patient Blood Management (PBM) initiative at Eastern Maine ... usage by more than 60 percent and improved patient ... detail in an article in the May 2015 edition ... perioperative red cell loss, less acute kidney injury and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 It was ... community foundation in Colorado. On Wednesday, May 13, The ... in a new era of community-based giving with its ... “Our Future in the Making,” the event celebrated the ... Denver Foundation to mobilize resources for good. , “If ...
(Date:5/26/2015)... 26, 2015 Relias Learning , ... the health and human services market, announces expansion of ... After strong attendance and participation in 2014, they will ... their annual user conference an exciting new facelift. ... come together and discuss best practices, share their expertise, ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 CIO Review has ... Most Promising Pharma and Life Sciences Technology Solution Providers. The ... Pat 11 compliant solution which is applicable across the entire ... ease-of-use necessary for broad adoption. , “SIGNiX has been ... in the Pharma and Life Sciences Technology space, and we ...
Breaking Medicine News(10 mins):Health News:Consumer Health Digest Official YouTube Channel: A Reliable Source of Health Information 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3Health News:Celebrating "Our Future in the Making" 2Health News:Celebrating "Our Future in the Making" 3Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3
... men over age 60 suffer from a non-cancerous enlargement ... urinary tract symptoms, and those symptoms are frequent urination, ... incomplete emptying of the bladder, etc.Based on the findings ... be better than one when it comes to treating ...
... that exercise improves the cognitive performance of people with ... findings from their recent study. ,Researchers studied 33 ... program after having bypass surgery, angioplasty or other procedures ... better emotionally and mentally after working out with or ...
... , Asian investigators suggest physicians should not recommend dexamethasone ... therapy routinely given to newborns to prevent or treat ... cognitive functioning by school age.Previous research shows dexamethasone, a ... the short-term and allows for early weaning from mechanical ...
... million Americans are allergic to fish and shellfish and ... is reported by 2.3 percent of the general population, ... a recent study researchers found about 2.3 percent of ... allergic to seafood. Researchers interviewed more than 5,500 households ...
... Coalition of Health for Asthmatics in Sports and Exercise and the ... to 127, 6- to 18-year olds who had at ... a 10-item questionnaire. The most common risk factor noted by children ... test, kids ran for eight to 10 minutes. Forced expiratory volume ...
... by Germany researchers shows young breast cancer survivors may ... As patients may not be getting the appropriate therapy ... ,Researchers sampled nearly 200 breast cancer patients who ... their physical symptoms and current therapy treatments. Results showed ...
Cached Medicine News:
For traditional abdominoplasty, Lipectomy of abdomen...
Ideal for abdominal procedures...
... creates a smoother fit in the abdominal ... The padded continuous hook and eye closures ... the extra strong, yet very thin zipper ... a reinforced open crotch, gripper lace trim, ...
For lipoplasty of trochanteric region, abdomen, thighs, hips/flanks, buttocks & knees...
Medicine Products: